|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DBT |
Gene summary for DBT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DBT | Gene ID | 1629 |
| Gene name | dihydrolipoamide branched chain transacylase E2 | |
| Gene Alias | BCATE2 | |
| Cytomap | 1p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P11182 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1629 | DBT | HCC1_Meng | Human | Liver | HCC | 1.16e-43 | 2.56e-02 | 0.0246 |
| 1629 | DBT | HCC2_Meng | Human | Liver | HCC | 1.16e-18 | 2.68e-02 | 0.0107 |
| 1629 | DBT | HCC1 | Human | Liver | HCC | 2.56e-26 | 2.94e+00 | 0.5336 |
| 1629 | DBT | HCC2 | Human | Liver | HCC | 7.01e-41 | 3.29e+00 | 0.5341 |
| 1629 | DBT | HCC5 | Human | Liver | HCC | 7.83e-30 | 2.02e+00 | 0.4932 |
| 1629 | DBT | S015 | Human | Liver | HCC | 2.05e-04 | 2.20e-01 | 0.2375 |
| 1629 | DBT | S027 | Human | Liver | HCC | 1.35e-02 | 3.19e-01 | 0.2446 |
| 1629 | DBT | S028 | Human | Liver | HCC | 1.29e-06 | 3.20e-01 | 0.2503 |
| 1629 | DBT | S029 | Human | Liver | HCC | 4.20e-06 | 3.45e-01 | 0.2581 |
| 1629 | DBT | C21 | Human | Oral cavity | OSCC | 3.10e-11 | 4.01e-01 | 0.2678 |
| 1629 | DBT | C30 | Human | Oral cavity | OSCC | 1.12e-10 | 5.06e-01 | 0.3055 |
| 1629 | DBT | C43 | Human | Oral cavity | OSCC | 2.13e-07 | 2.42e-01 | 0.1704 |
| 1629 | DBT | C46 | Human | Oral cavity | OSCC | 1.60e-05 | 1.81e-01 | 0.1673 |
| 1629 | DBT | C51 | Human | Oral cavity | OSCC | 1.44e-02 | 3.65e-01 | 0.2674 |
| 1629 | DBT | C57 | Human | Oral cavity | OSCC | 3.88e-05 | 1.66e-01 | 0.1679 |
| 1629 | DBT | LN22 | Human | Oral cavity | OSCC | 1.00e-03 | 5.59e-01 | 0.1733 |
| 1629 | DBT | SYSMH2 | Human | Oral cavity | OSCC | 2.62e-04 | 1.87e-01 | 0.2326 |
| 1629 | DBT | SYSMH3 | Human | Oral cavity | OSCC | 8.62e-10 | 3.25e-01 | 0.2442 |
| 1629 | DBT | SYSMH6 | Human | Oral cavity | OSCC | 1.67e-04 | 1.54e-01 | 0.1275 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0028041 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
| hsa0064041 | Liver | HCC | Propanoate metabolism | 24/4020 | 32/8465 | 1.42e-03 | 5.07e-03 | 2.82e-03 | 24 |
| hsa00785 | Liver | HCC | Lipoic acid metabolism | 14/4020 | 19/8465 | 1.89e-02 | 4.40e-02 | 2.45e-02 | 14 |
| hsa0028051 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
| hsa0064051 | Liver | HCC | Propanoate metabolism | 24/4020 | 32/8465 | 1.42e-03 | 5.07e-03 | 2.82e-03 | 24 |
| hsa007851 | Liver | HCC | Lipoic acid metabolism | 14/4020 | 19/8465 | 1.89e-02 | 4.40e-02 | 2.45e-02 | 14 |
| hsa002807 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
| hsa0028012 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DBT | SNV | Missense_Mutation | novel | c.868C>A | p.Leu290Ile | p.L290I | P11182 | protein_coding | tolerated(0.07) | benign(0.1) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DBT | SNV | Missense_Mutation | c.268G>C | p.Asp90His | p.D90H | P11182 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DBT | SNV | Missense_Mutation | c.771A>C | p.Lys257Asn | p.K257N | P11182 | protein_coding | deleterious(0.02) | benign(0.024) | TCGA-A6-2681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DBT | SNV | Missense_Mutation | c.713N>A | p.Pro238His | p.P238H | P11182 | protein_coding | deleterious(0.01) | possibly_damaging(0.646) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DBT | SNV | Missense_Mutation | rs766629953 | c.536G>A | p.Arg179His | p.R179H | P11182 | protein_coding | deleterious(0.02) | possibly_damaging(0.599) | TCGA-AD-6890-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| DBT | SNV | Missense_Mutation | c.584G>T | p.Gly195Val | p.G195V | P11182 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DBT | SNV | Missense_Mutation | c.1163C>T | p.Thr388Ile | p.T388I | P11182 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| DBT | SNV | Missense_Mutation | c.272C>T | p.Thr91Ile | p.T91I | P11182 | protein_coding | tolerated(0.12) | benign(0.02) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| DBT | SNV | Missense_Mutation | c.886N>A | p.Pro296Thr | p.P296T | P11182 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DBT | SNV | Missense_Mutation | c.350T>C | p.Val117Ala | p.V117A | P11182 | protein_coding | tolerated(0.05) | benign(0.301) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |